The promise of TRAIL - potential and risks of a novel anticancer therapy

被引:182
作者
Koschny, Ronald
Walczak, Henning
Ganten, Tom M.
机构
[1] Heidelberg Univ, Dept Gastroenterol Internal Med, D-69120 Heidelberg, Germany
[2] German Canc Res Ctr, Div Apoptosis Regulat, Heidelberg, Germany
来源
JOURNAL OF MOLECULAR MEDICINE-JMM | 2007年 / 85卷 / 09期
关键词
TRAIL-induced apoptosis; toxicity; primary tumor cells; sensitization; chemotherapeutics;
D O I
10.1007/s00109-007-0194-1
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising new anticancer biotherapeutic. As shown by many preclinical studies, TRAIL efficiently induces apoptosis in numerous tumor cell lines but not in the majority of normal cells. However, an increasing number of publications report on a predominance of TRAIL resistance in primary human tumor cells, which require sensitization for TRAIL-induced apoptosis. Sensitization of cancer cells by treatment with chemotherapeutic drugs and irradiation has been shown to restore TRAIL sensitivity in many TRAIL-resistant tumor cells. Accordingly TRAIL treatment has been successfully used in different in vivo models for the treatment of tumors also in combination with chemotherapeutics without significant toxicity. However, some reports demonstrated toxicity of TRAIL alone or in combination with chemotherapeutic drugs in normal cells. This review summarizes data concerning the apoptosis-inducing pathways and efficacy of TRAIL, alone or in combination with chemotherapeutic drugs, in primary cancer cells compared to the unwanted effects of TRAIL treatment on normal tissue. We discuss the different in vitro tumor cell models and the potential of different recombinant forms of TRAIL or agonistic antibodies to TRAIL death receptors. Most preclinical studies show a high efficiency of a combinatorial TRAIL-based therapy in animal models and in primary human ex vivo tumor cells with a low toxicity in normal cells. Accordingly clinical phase I/II studies have begun and will be developed further with caution.
引用
收藏
页码:923 / 935
页数:13
相关论文
共 127 条
[51]   Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human Esophageal epithelial cells [J].
Kim, SH ;
Kim, K ;
Kwagh, JG ;
Dicker, DT ;
Herlyn, M ;
Rustgi, AK ;
Chen, YH ;
El-Deiry, WS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (38) :40044-40052
[52]   TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window [J].
Koschny, Ronald ;
Ganten, Tom M. ;
Sykora, Jaromir ;
Haas, Tobias L. ;
Sprick, Martin R. ;
Kolb, Armin ;
Stremmel, Wolfgang ;
Walczak, Henning .
HEPATOLOGY, 2007, 45 (03) :649-658
[53]   Interleukin-1 protects transformed keratinocytes from tumor necrosis factor-related apoptosis-inducing ligand [J].
Kothny-Wilkes, G ;
Kulms, D ;
Pöppelmann, B ;
Luger, TA ;
Kubin, M ;
Schwarz, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (44) :29247-29253
[54]   Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions [J].
Lawrence, D ;
Shahrokh, Z ;
Marsters, S ;
Achilles, K ;
Shih, D ;
Mounho, B ;
Hillan, K ;
Totpal, K ;
DeForge, L ;
Schow, P ;
Hooley, J ;
Sherwood, S ;
Pai, R ;
Leung, S ;
Khan, LL ;
Gliniak, B ;
Bussiere, J ;
Smith, CA ;
Strom, SS ;
Kelley, S ;
Fox, JA ;
Thomas, D ;
Ashkenazi, A .
NATURE MEDICINE, 2001, 7 (04) :383-385
[55]  
Leverkus M, 2000, CANCER RES, V60, P553
[56]   Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation [J].
Leverkus, M ;
Sprick, MR ;
Wachter, T ;
Mengling, T ;
Baumann, B ;
Serfling, E ;
Bröcker, EB ;
Goebeler, M ;
Neumann, M ;
Walczak, H .
MOLECULAR AND CELLULAR BIOLOGY, 2003, 23 (03) :777-790
[57]   TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells [J].
Li, JH ;
Kirkiles-Smith, NC ;
McNiff, JM ;
Pober, JS .
JOURNAL OF IMMUNOLOGY, 2003, 171 (03) :1526-1533
[58]   Hepatitis B virus sensitizes hepatocytes to TRAIL-induced apoptosis through Bax [J].
Liang, Xiaohong ;
Liu, Yugang ;
Zhang, Qiu ;
Gao, Lifen ;
Han, Lihui ;
Ma, Chunhong ;
Zhang, Lining ;
Chen, Youhai H. ;
Sun, Wensheng .
JOURNAL OF IMMUNOLOGY, 2007, 178 (01) :503-510
[59]   Blockade of TRAIL pathway ameliorates HBV-induced hepatocyte apoptosis in an acute hepatitis model [J].
Liu, Yu-Gang ;
Liu, Su-Xia ;
Liang, Xiao-Hong ;
Zhang, Qiu ;
Gao, Li-Fen ;
Han, Li-Hui ;
Cao, Ying-Lin ;
Hou, Nan ;
Du, Juan ;
Sun, Wen-Sheng .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2007, 352 (02) :329-334
[60]   TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies [J].
MacFarlane, M ;
Kohlhaas, SL ;
Sutcliffe, MJ ;
Dyer, MJS ;
Cohen, GM .
CANCER RESEARCH, 2005, 65 (24) :11265-11270